Ocuphire Pharma
summary of trial results | Ocuphire Pharma
Company
Deck Type
Deck date
May 2023
Slide
21 of 27
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Investor Presentation
November 2023
summary of ophthalmic solution trial results post dose bree nea mild | Ocuphire Pharma
Investor Presentation
August 2023
summary of trial results | Ocuphire Pharma
Related slides by other companies
Aeglea BioTherapeutics
Results
December 2021
primary met marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
ATAI
Investor Presentation
September 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Nuvectis Pharma
Investor Presentation
December 2023
phase underway fast track designation | Nuvectis Pharma
Bausch Health Companies
Results
May 2022
progress in late stage product development development salix | Bausch Health Companies
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights